Drug Delivery Business

  • Discovery
    • Technology
  • Research & Development
  • Preclinical Trials
  • Clinical Trials
  • Policy
  • Contract Services
  • Diagnostics

Bigfoot Biomedical inks insulin deal with Eli Lilly

January 7, 2019 By Sarah Faulkner Leave a Comment

Bigfoot Biomedical updated logo

Bigfoot Biomedical said today that it inked a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices. The California-based company expects to launch its first two insulin delivery systems – Bigfoot Inject and Bigfoot Loop – in 2020, contingent upon finishing a pivotal trial and landing regulatory […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: abbott, Bigfoot Biomedical, Eli Lilly & Co.

Abbott wins FDA nod for FreeStyle Libre’s mobile app

November 1, 2018 By Sarah Faulkner Leave a Comment

Abbott logo updated

Abbott (NYSE:ABT) said today that it won FDA approval for a mobile app that is designed for the company’s FreeStyle Libre continuous glucose monitoring system. The FreeStyle LibreLink app allows users to capture and view their glucose data in real-time using their mobile phones. Prior to the mobile app, people using Abbott’s FreeStyle Libre CGM had […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: abbott

Abbott CEO on Libre: ‘We’re just getting started’

October 18, 2018 By Sarah Faulkner Leave a Comment

Abbott logo updated

Abbott (NYSE:ABT) posted its third quarter financial results yesterday, meeting its own forecast and the consensus set by analysts on Wall Street. The healthcare giant also narrowed its earnings outlook for the rest of the year. Abbott noted particularly high gains in revenue for its medical device division – sales were up 8.4% to $2.82 billion, in […]

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: abbott

Abbott’s next-gen FreeStyle Libre wins CE Mark

October 1, 2018 By Sarah Faulkner 4 Comments

Abbott logo updated

Abbott (NYSE:ABT) said today that its next-generation FreeStyle Libre system won CE Mark clearance in the European Union. The glucose monitor, which eliminates the need for finger sticks, features optional alarms that users can customize, according to Abbott. “The FreeStyle Libre 2 system is designed to further empower people with diabetes by providing a choice about […]

Filed Under: Diabetes, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: abbott

TCT 2018: Boston Scientific wins FDA nod for drug-eluting vascular stent

September 24, 2018 By Sarah Faulkner Leave a Comment

Boston Scientific

On the heels of positive study results at the 30th Transcatheter Cardiovascular Therapeutics meeting, Boston Scientific (NYSE:BSX) won FDA approval for its drug-eluting vascular stent system, Eluvia. The device, which is designed for the treatment of peripheral artery disease, uses a drug-polymer combination to deliver paclitaxel over the course of a year. “Over the past decade, we’ve […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Vascular, Wall Street Beat Tagged With: abbott, biosensors, Biotronik, Boston Scientific, cook medical, Medtronic, TCT 2018

Livongo adds compatibility with Abbott’s FreeStyle Libre Pro

September 5, 2018 By Fink Densford Leave a Comment

Livongo, Abbott

Livongo Health said today it will integrate continuous glucose data from Abbott‘s (NYSE:ABT) FreeStyle Libre Pro system into its Livongo for Diabetes system, touting it as the first such system to integrate data from Abbott’s FreeStyle Libre Pro. With the integration, users of the FreeStyle Libre Pro will be able to see a visual snapshot of […]

Filed Under: Business/Financial News, Diabetes, Featured Tagged With: abbott, livongohealth

MicroPort’s drug-eluting stent performs well in European study

September 4, 2018 By Nancy Crotti Leave a Comment

MicroPort Scientific’s Firehawk rapamycin target eluting coronary stent performed comparably to Abbott’s Xience stent family in a study just published in The Lancet. The TARGET AC multi-center, randomized controlled trial enrolled 1,653 patients at 21 clinical study sites in Europe. Firehawk met the trial’s non-inferiority primary endpoint of target lesion failure rate at 12 months of 6.1% versus […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Implants, Stents, Uncategorized Tagged With: abbott, microportscientific

Abbott wins FDA nod for 14-day FreeStyle Libre glucose sensor

July 27, 2018 By Sarah Faulkner Leave a Comment

Abbott's FreeStyle Libre

Abbott (NYSE:ABT) said today that the FDA approved its 14-day FreeStyle Libre flash glucose monitor, making the device the longest lasting self-applied glucose sensor on the market. The company’s FreeStyle Libre system, initially approved to last 10 days, is designed to eliminate the need for fingersticks. Users can test their blood sugar with the continuous glucose […]

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), mHealth (Mobile Health), Regulatory/Compliance, Wall Street Beat Tagged With: abbott

Abbott CEO aims for more than one million Libre users by 2019

July 19, 2018 By Sarah Faulkner Leave a Comment

Abbott

Topping estimates on Wall Street, Abbott (NYSE:ABT) posted a hefty beat yesterday with its second-quarter financial results. Driving the company’s growth was, in part, its diabetes business unit – sales jumped nearly 40% compared to Q2 in 2017 thanks largely to its sensor-based glucose monitoring system, Freestyle Libre. “Libre offers a true mass-market opportunity with its […]

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup, mHealth (Mobile Health), Patient Monitoring, Wall Street Beat Tagged With: abbott

Sales for Abbott’s diabetes business jump 40% in Q2

July 18, 2018 By Sarah Faulkner Leave a Comment

Abbott's FreeStyle Libre

Abbott (NYSE:ABT) shares were up today after the healthcare company posted second-quarter financial results that topped estimates on Wall Street. For the three months ended June 30, Abbott posted profits of $733 million, or 41¢ per share, on sales of $7.77 billion. The company saw its quarterly profits grow 159% on sales growth of 17% compared […]

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup, Vascular, Wall Street Beat Tagged With: abbott

  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS